Tuberculosis Meningitis

Current Infectious Disease Reports

Volumn 19, Issue 11, 2017, Pages

  Bourgi, Kassem ^a   Fiske, Christina ^a   Sterling, Timothy R ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Central nervous system (CNS); Cerebrospinal fluid (CSF); Tuberculosis (TB)

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DEAMINASE; ANTIRETROVIRUS AGENT; CORTICOSTEROID; ETHAMBUTOL; ISONIAZID; MOXIFLOXACIN; PYRAZINAMIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; STEROID;

ANTIRETROVIRAL THERAPY; BACTERIAL STRAIN; CEREBROSPINAL FLUID ANALYSIS; DISEASE ASSOCIATION; DRUG DOSE INCREASE; DRUG DOSE INTENSIFICATION; DRUG EFFICACY; EARLY DIAGNOSIS; HIGH RISK PATIENT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; INFECTION RATE; INFECTION RISK; INTERFERON GAMMA RELEASE ASSAY; MICROSCOPY; MIXED INFECTION; NEUROSURGERY; NONHUMAN; NUCLEIC ACID AMPLIFICATION; PREVALENCE; PROGNOSIS; RADIODIAGNOSIS; REVIEW; SCREENING TEST; SENSITIVITY AND SPECIFICITY; STAINING; SURVIVAL; SYMPTOM; TREATMENT DURATION; TUBERCULOSIS RAPID TEST; TUBERCULOUS MENINGITIS; TURNAROUND TIME; UNSPECIFIED SIDE EFFECT;

EID: 85029535805     PISSN: 15233847     EISSN: 15343146     Source Type: Journal    
DOI: 10.1007/s11908-017-0595-4     Document Type: Review

References (102)

1. Van TT, Farrar J. Tuberculous meningitis. J Epidemiol Community Health. 2014;68(3):195–6. https://doi.org/10.1136/jech-2013-202525.
2. Rock RB, Olin M, Baker CA, Molitor TW, Peterson PK. Central nervous system tuberculosis: pathogenesis and clinical aspects. Clin Microbiol Rev. 2008;21(2):243–261, table of contents. https://doi.org/10.1128/CMR.00042-07.
3. Thwaites GE, van Toorn R, Schoeman J. Tuberculous meningitis: more questions, still too few answers. Lancet Neurol. 2013;12(10):999–1010. https://doi.org/10.1016/S1474-4422(13)70168-6.
4. Torok ME. Tuberculous meningitis: advances in diagnosis and treatment. Br Med Bull. 2015;113(1):117–31. https://doi.org/10.1093/bmb/ldv003.
5. World Health Organization. Global tuberculosis report 2016. 2016.
6. Murthy JM. Tuberculous meningitis: the challenges. Neurol India. 2010;58(5):716–22. https://doi.org/10.4103/0028-3886.72178.
7. van Well GT, Paes BF, Terwee CB, Springer P, Roord JJ, Donald PR, et al. Twenty years of pediatric tuberculous meningitis: a retrospective cohort study in the western cape of South Africa. Pediatrics. 2009;123(1):e1–8.
8. Berenguer J, Moreno S, Laguna F, Vicente T, Adrados M, Ortega A, et al. Tuberculous meningitis in patients infected with the human immunodeficiency virus. N Engl J Med. 1992;326(10):668–72. https://doi.org/10.1056/NEJM199203053261004.
9. Kingkaew N, Sangtong B, Amnuaiphon W, Jongpaibulpatana J, Mankatittham W, Akksilp S, et al. HIV-associated extrapulmonary tuberculosis in Thailand: epidemiology and risk factors for death. Int J Infect Dis. 2009;13(6):722–9. https://doi.org/10.1016/j.ijid.2008.11.013.
10. Leeds IL, Magee MJ, Kurbatova EV, del Rio C, Blumberg HM, Leonard MK, et al. Site of extrapulmonary tuberculosis is associated with HIV infection. Clin Infect Dis. 2012;55(1):75–81.
11. Schoeman JF, Donald PR. Chapter 117—tuberculous meningitis. In: Olivier Dulac ML, Harvey BS, editors. Handbook of clinical neurology. Elsevier; 2013. p. 1135–8.
12. Thwaites GE, Nguyen DB, Nguyen HD, Hoang TQ, Do TT, Nguyen TC, et al. Dexamethasone for the treatment of tuberculous meningitis in adolescents and adults. N Engl J Med. 2004;351(17):1741–51. https://doi.org/10.1056/NEJMoa040573.
13. Sinha MK, Garg RK, Anuradha H, Agarwal A, Singh MK, Verma R, et al. Vision impairment in tuberculous meningitis: predictors and prognosis. J Neurol Sci. 2010;290(1–2):27–32. https://doi.org/10.1016/j.jns.2009.12.012.
14. Mai NT, Thwaites GE. Recent advances in the diagnosis and management of tuberculous meningitis. Curr Opin Infect Dis. 2017;30(1):123–8. https://doi.org/10.1097/QCO.0000000000000331.
15. Schmit KM, Wansaula Z, Pratt R, Price SF, Langer AJ. Tuberculosis—United States, 2016. MMWR Morb Mortal Wkly Rep. 2017;66(11):289–94. https://doi.org/10.15585/mmwr.mm6611a2.
16. Centers for Disease Control and Prevention (CDC). Reported tuberculosis in the United States, 2015. Atlanta: US Department of Health and Human Services, CDC; 2016.
17. Peto HM, Pratt RH, Harrington TA, LoBue PA, Armstrong LR. Epidemiology of extrapulmonary tuberculosis in the United States, 1993-2006. Clin Infect Dis. 2009;49(9):1350–7. https://doi.org/10.1086/605559.
18. Pehlivanoglu F, Yasar KK, Sengoz G. Tuberculous meningitis in adults: a review of 160 cases. ScientificWorldJournal. 2012;2012:169028. https://doi.org/10.1100/2012/169028.
19. Sharma P, Garg RK, Verma R, Singh MK, Shukla R. Incidence, predictors and prognostic value of cranial nerve involvement in patients with tuberculous meningitis: a retrospective evaluation. Eur J Intern Med. 2011;22(3):289–95. https://doi.org/10.1016/j.ejim.2011.01.007.
20. Youssef FG, Afifi SA, Azab AM, Wasfy MM, Abdel-Aziz KM, Parker TM, et al. Differentiation of tuberculous meningitis from acute bacterial meningitis using simple clinical and laboratory parameters. Diagn Microbiol Infect Dis. 2006;55(4):275–8.
21. Hristea A, Olaru ID, Baicus C, Moroti R, Arama V, Ion M. Clinical prediction rule for differentiating tuberculous from viral meningitis. Int J Tuberc Lung Dis. 2012;16(6):793–8. https://doi.org/10.5588/ijtld.11.0687.
22. Vibha D, Bhatia R, Prasad K, Srivastava MP, Tripathi M, Kumar G, et al. Validation of diagnostic algorithm to differentiate between tuberculous meningitis and acute bacterial meningitis. Clin Neurol Neurosurg. 2012;114(6):639–44.
23. Zhang YL, Lin S, Shao LY, Zhang WH, Weng XH. Validation of Thwaites’ diagnostic scoring system for the differential diagnosis of tuberculous meningitis and bacterial meningitis. Jpn J Infect Dis. 2014;67(6):428–31.
24. Cohen DB, Zijlstra EE, Mukaka M, Reiss M, Kamphambale S, Scholing M, et al. Diagnosis of cryptococcal and tuberculous meningitis in a resource-limited African setting. Tropical Med Int Health. 2010;15(8):910–7. https://doi.org/10.1111/j.1365-3156.2010.02565.x.
25. Patel VB, Singh R, Connolly C, Kasprowicz V, Zumla A, Ndungu T, et al. Comparison of a clinical prediction rule and a LAM antigen-detection assay for the rapid diagnosis of TBM in a high HIV prevalence setting. PLoS One. 2010;5(12):e15664. https://doi.org/10.1371/journal.pone.0015664.
26. Jackson A, van der Horst C. New insights in the prevention, diagnosis, and treatment of cryptococcal meningitis. Curr HIV/AIDS Rep. 2012;9(3):267–77. https://doi.org/10.1007/s11904-012-0127-7.
27. Erdem H, Ozturk-Engin D, Elaldi N, Gulsun S, Sengoz G, Crisan A, et al. The microbiological diagnosis of tuberculous meningitis: results of Haydarpasa-1 study. Clin Microbiol Infect. 2014;20(10):O600–8. https://doi.org/10.1111/1469-0691.12478.
28. Thwaites GE, Chau TT, Farrar JJ. Improving the bacteriological diagnosis of tuberculous meningitis. J Clin Microbiol. 2004;42(1):378–9.
29. Chen P, Shi M, Feng GD, Liu JY, Wang BJ, Shi XD, et al. A highly efficient Ziehl-Neelsen stain: identifying de novo intracellular Mycobacterium tuberculosis and improving detection of extracellular M. tuberculosis in cerebrospinal fluid. J Clin Microbiol. 2012;50(4):1166–70. https://doi.org/10.1128/JCM.05756-11.
30. Feng GD, Shi M, Ma L, Chen P, Wang BJ, Zhang M, et al. Diagnostic accuracy of intracellular mycobacterium tuberculosis detection for tuberculous meningitis. Am J Respir Crit Care Med. 2014;189(4):475–81. https://doi.org/10.1164/rccm.201309-1686OC.
31. Caws M, Dang TM, Torok E, Campbell J, Do DA, Tran TH, et al. Evaluation of the MODS culture technique for the diagnosis of tuberculous meningitis. PLoS One. 2007;2(11):e1173. https://doi.org/10.1371/journal.pone.0001173.
32. Tuon FF, Higashino HR, Lopes MI, Litvoc MN, Atomiya AN, Antonangelo L, et al. Adenosine deaminase and tuberculous meningitis—a systematic review with meta-analysis. Scand J Infect Dis. 2010;42(3):198–207. https://doi.org/10.3109/00365540903428158.
33. Corral I, Quereda C, Navas E, Martin-Davila P, Perez-Elias MJ, Casado JL, et al. Adenosine deaminase activity in cerebrospinal fluid of HIV-infected patients: limited value for diagnosis of tuberculous meningitis. Eur J Clin Microbiol Infect Dis. 2004;23(6):471–6. https://doi.org/10.1007/s10096-004-1110-z.
34. Pai M, Flores LL, Pai N, Hubbard A, Riley LW, Colford JM Jr. Diagnostic accuracy of nucleic acid amplification tests for tuberculous meningitis: a systematic review and meta-analysis. Lancet Infect Dis. 2003;3(10):633–43.
35. Takahashi T, Nakayama T. Novel technique of quantitative nested real-time PCR assay for Mycobacterium tuberculosis DNA. J Clin Microbiol. 2006;44(3):1029–39. https://doi.org/10.1128/JCM.44.3.1029-1039.2006.
36. Bhigjee AI, Padayachee R, Paruk H, Hallwirth-Pillay KD, Marais S, Connoly C. Diagnosis of tuberculous meningitis: clinical and laboratory parameters. Int J Infect Dis. 2007;11(4):348–54. https://doi.org/10.1016/j.ijid.2006.07.007.
37. Boehme CC, Nabeta P, Hillemann D, Nicol MP, Shenai S, Krapp F, et al. Rapid molecular detection of tuberculosis and rifampin resistance. N Engl J Med. 2010;363(11):1005–15. https://doi.org/10.1056/NEJMoa0907847.
38. Lawn SD, Nicol MP. Xpert® MTB/RIF assay: development, evaluation and implementation of a new rapid molecular diagnostic for tuberculosis and rifampicin resistance. Future Microbiol. 2011;6(9):1067–82.
39. Chang K, Lu W, Wang J, Zhang K, Jia S, Li F, et al. Rapid and effective diagnosis of tuberculosis and rifampicin resistance with Xpert MTB/RIF assay: a meta-analysis. J Inf Secur. 2012;64(6):580–8. https://doi.org/10.1016/j.jinf.2012.02.012.
40. Patel VB, Theron G, Lenders L, Matinyena B, Connolly C, Singh R, et al. Diagnostic accuracy of quantitative PCR (Xpert MTB/RIF) for tuberculous meningitis in a high burden setting: a prospective study. PLoS Med. 2013;10(10):e1001536. https://doi.org/10.1371/journal.pmed.1001536.
41. Nhu NT, Heemskerk D, do DA T, Chau TT, Mai NT, Nghia HD, et al. Evaluation of GeneXpert MTB/RIF for diagnosis of tuberculous meningitis. J Clin Microbiol. 2014;52(1):226–33. https://doi.org/10.1128/JCM.01834-13.
42. Denkinger CM, Schumacher SG, Boehme CC, Dendukuri N, Pai M, Steingart KR. Xpert MTB/RIF assay for the diagnosis of extrapulmonary tuberculosis: a systematic review and meta-analysis. Eur Respir J. 2014;44(2):435–46. https://doi.org/10.1183/09031936.00007814.
43. World Health Organization. Xpert MTB/RIF assay for the diagnosis of pulmonary and extrapulmonary TB in adults and children: policy update. 2013.
44. Bahr NC, Tugume L, Rajasingham R, Kiggundu R, Williams DA, Morawski B, et al. Improved diagnostic sensitivity for tuberculous meningitis with Xpert((R)) MTB/RIF of centrifuged CSF. Int J Tuberc Lung Dis. 2015;19(10):1209–15. https://doi.org/10.5588/ijtld.15.0253.
45. Bahr NC, Marais S, Caws M, van Crevel R, Wilkinson RJ, Tyagi JS, et al. GeneXpert MTB/RIF to diagnose tuberculous meningitis: perhaps the first test but not the last. Clin Infect Dis. 2016;62(9):1133–5.
46. Cepheid. 2017 launch of new TB test Ultra backed by WHO recommendation. http://www.cepheid.com/us/about-us/news-events/press-releases/216-2017-launch-of-new-tb-test-ultra-backed-by-who-recommendation. Accessed 08/10/2017.
47. WHO meeting report of a technical expert consultation: non-inferiority analysis of Xpert MTF/RIF Ultra compared to Xpert MTB/RIF. Geneva: World Health Organization; 2017 (WHO/HTM/TB/2017.04). Licence: CC BY-NCSA 3.0 IGO.
48. Mazurek GH, Jereb J, Vernon A, LoBue P, Goldberg S, Castro K, et al. Updated guidelines for using interferon gamma release assays to detect Mycobacterium tuberculosis infection-United States, 2010. MMWR Recomm Rep. 2010;59(RR-5):1–25.
49. Patel VB, Singh R, Connolly C, Coovadia Y, Peer AK, Parag P, et al. Cerebrospinal T-cell responses aid in the diagnosis of tuberculous meningitis in a human immunodeficiency virus- and tuberculosis-endemic population. Am J Respir Crit Care Med. 2010;182(4):569–77. https://doi.org/10.1164/rccm.200912-1931OC.
50. Kim SH, Cho OH, Park SJ, Lee EM, Kim MN, Lee SO, et al. Rapid diagnosis of tuberculous meningitis by T cell-based assays on peripheral blood and cerebrospinal fluid mononuclear cells. Clin Infect Dis. 2010;50(10):1349–58. https://doi.org/10.1086/652142.
51. Yu J, Wang ZJ, Chen LH, Li HH. Diagnostic accuracy of interferon-gamma release assays for tuberculous meningitis: a meta-analysis. Int J Tuberc Lung Dis. 2016;20(4):494–9. https://doi.org/10.5588/ijtld.15.0600.
52. Torres C, Riascos R, Figueroa R, Gupta RK. Central nervous system tuberculosis. Top Magn Reson Imaging. 2014;23(3):173–89. https://doi.org/10.1097/RMR.0000000000000023.
53. Pienaar M, Andronikou S, van Toorn R. MRI to demonstrate diagnostic features and complications of TBM not seen with CT. Childs Nerv Syst. 2009;25(8):941–7. https://doi.org/10.1007/s00381-008-0785-3.
54. Botha H, Ackerman C, Candy S, Carr JA, Griffith-Richards S, Bateman KJ. Reliability and diagnostic performance of CT imaging criteria in the diagnosis of tuberculous meningitis. PLoS One. 2012;7(6):e38982. https://doi.org/10.1371/journal.pone.0038982.
55. Kalita J, Prasad S, Maurya PK, Kumar S, Misra UKMR. Angiography in tuberculous meningitis. Acta Radiol. 2012;53(3):324–9. https://doi.org/10.1258/ar.2012.110712.
56. Nahid P, Dorman SE, Alipanah N, Barry PM, Brozek JL, Cattamanchi A, et al. Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America clinical practice guidelines: treatment of drug-susceptible tuberculosis. Clin Infect Dis. 2016;63(7):e147–e95. https://doi.org/10.1093/cid/ciw376.
57. World Health Organization, Stop TB Initiative. Treatment of tuberculosis: guidelines. Geneva: World Health Organization; 2010.
58. Thwaites G, Fisher M, Hemingway C, Scott G, Solomon T, Innes J, et al. British Infection Society guidelines for the diagnosis and treatment of tuberculosis of the central nervous system in adults and children. J Inf Secur. 2009;59(3):167–87. https://doi.org/10.1016/j.jinf.2009.06.011.
59. World Health Organization. Guidelines for the treatment of drug-susceptible tuberculosis and patient care, 2017 update. 2017.
60. Nelson CA, Zunt JR. Tuberculosis of the central nervous system in immunocompromised patients: HIV infection and solid organ transplant recipients. Clin Infect Dis. 2011;53(9):915–26. https://doi.org/10.1093/cid/cir508.
61. • Heemskerk AD, Bang ND, Mai NT, Chau TT, Phu NH, Loc PP, et al. Intensified antituberculosis therapy in adults with tuberculous meningitis. N Engl J Med. 2016;374(2):124–34. https://doi.org/10.1056/NEJMoa1507062. This randomized clinical trial conducted at two centers in Vietnam evaluated whether TB meningitis survival rates improved with treatment intensification through increased rifampin dosing and adding levofloxacin. During 9 months of follow-up and compared to patients treated with standard therapy, treatment intensification did not confer a significant survival benefit. Moreover, intensified treatment was associated with increased, albeit not statistically significant, rates of adverse events.
62. Ruslami R, Ganiem AR, Dian S, Apriani L, Achmad TH, van der Ven AJ, et al. Intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitis: an open-label, randomised controlled phase 2 trial. Lancet Infect Dis. 2013;13(1):27–35. https://doi.org/10.1016/S1473-3099(12)70264-5.
63. Thwaites GE, Bhavnani SM, Chau TT, Hammel JP, Torok ME, Van Wart SA, et al. Randomized pharmacokinetic and pharmacodynamic comparison of fluoroquinolones for tuberculous meningitis. Antimicrob Agents Chemother. 2011;55(7):3244–53. https://doi.org/10.1128/AAC.00064-11.
64. Torok ME, Aljayyoussi G, Waterhouse D, Chau T, Mai N, Phu NH, et al. Suboptimal exposure to anti-TB drugs in a TBM/HIV+ population is not related to anti-retroviral therapy. Clin Pharmacol Ther. 2017; https://doi.org/10.1002/cpt.646.
65. van Loenhout-Rooyackers JH, Keyser A, Laheij RJ, Verbeek AL, van der Meer JW. Tuberculous meningitis: is a 6-month treatment regimen sufficient? Int J Tuberc Lung Dis. 2001;5(11):1028–35.
66. Jullien S, Ryan H, Modi M, Bhatia R. Six months therapy for tuberculous meningitis. Cochrane Database Syst Rev. 2016;9:CD012091. https://doi.org/10.1002/14651858.CD012091.pub2.
67. Garg RK, Jain A, Malhotra HS, Agrawal A, Garg R. Drug-resistant tuberculous meningitis. Expert Rev Anti-Infect Ther. 2013;11(6):605–21. https://doi.org/10.1586/eri.13.39.
68. Vinnard C, Winston CA, Wileyto EP, Macgregor RR, Bisson GP. Isoniazid resistance and death in patients with tuberculous meningitis: retrospective cohort study. BMJ. 2010;341:c4451. https://doi.org/10.1136/bmj.c4451.
69. Nagarathna S, Rafi W, Veenakumari HB, Mani R, Satishchandra P, Chandramuki A. Drug susceptibility profiling of tuberculous meningitis. Int J Tuberc Lung Dis. 2008;12(1):105–7.
70. World Health Organization. Guidance for national tuberculosis programmes on the management of tuberculosis in children. Geneva: World Health Organization; 2014.
71. Prasad K, Singh MB, Ryan H. Corticosteroids for managing tuberculous meningitis. Cochrane Database Syst Rev. 2016;4:CD002244. https://doi.org/10.1002/14651858.CD002244.pub4.
72. Critchley JA, Young F, Orton L, Garner P. Corticosteroids for prevention of mortality in people with tuberculosis: a systematic review and meta-analysis. Lancet Infect Dis. 2013;13(3):223–37. https://doi.org/10.1016/S1473-3099(12)70321-3.
73. Kilincoglu BF, Dalkilic T, Dincbal MN, Aydin Y. Shunting in hydrocephalus due to tuberculous meningitis. Cases presenting with high cerebrospinal fluid proteins in pediatric age. J Neurosurg Sci. 2009;53(2):49–53.
74. Misra UK, Kalita J, Nair PP. Role of aspirin in tuberculous meningitis: a randomized open label placebo controlled trial. J Neurol Sci. 2010;293(1–2):12–7. https://doi.org/10.1016/j.jns.2010.03.025.
75. Schoeman JF, Janse van Rensburg A, Laubscher JA, Springer P. The role of aspirin in childhood tuberculous meningitis. J Child Neurol. 2011;26(8):956–62. https://doi.org/10.1177/0883073811398132.
76. Yang Z, Kong Y, Wilson F, Foxman B, Fowler AH, Marrs CF, et al. Identification of risk factors for extrapulmonary tuberculosis. Clin Infect Dis. 2004;38(2):199–205. https://doi.org/10.1086/380644.
77. Rajasingham R, Rhein J, Klammer K, Musubire A, Nabeta H, Akampurira A, et al. Epidemiology of meningitis in an HIV-infected Ugandan cohort. Am J Trop Med Hyg. 2015;92(2):274–9. https://doi.org/10.4269/ajtmh.14-0452.
78. Thwaites GE, Duc Bang N, Huy Dung N, Thi Quy H, Thi Tuong Oanh D, Thi Cam Thoa N, et al. The influence of HIV infection on clinical presentation, response to treatment, and outcome in adults with tuberculous meningitis. J Infect Dis. 2005;192(12):2134–41. https://doi.org/10.1086/498220.
79. Cecchini D, Ambrosioni J, Brezzo C, Corti M, Rybko A, Perez M, et al. Tuberculous meningitis in HIV-infected and non-infected patients: comparison of cerebrospinal fluid findings [short communication]. Int J Tuberc Lung Dis. 2009;13(2):269–71.
80. Vidal J, Penalva de Oliveira A, Hernández A. CD4+ T-cell count and cerebrospinal fluid findings in HIV-infected patients with tuberculous meningitis [correspondence]. Int J Tuberc Lung Dis. 2010;14(11):1496–7.
81. Puccioni-Sohler M, Brandão CO. Factors associated to the positive cerebrospinal fuid culture in the tuberculous meningitis. Arq Neuropsiquiatr. 2007;65(1):48–53.
82. Chamie G, Marquez C, Luetkemeyer A. HIV-associated central nervous system tuberculosis. Semin Neurol. 2014;34(1):103–15. https://doi.org/10.1055/s-0034-1372347.
83. Laureillard D, Marcy O, Madec Y, Chea S, Chan S, Borand L, et al. Paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome after early initiation of antiretroviral therapy in a randomized clinical trial. AIDS. 2013;27(16):2577–86. https://doi.org/10.1097/01.aids.0000432456.14099.c7.
84. Marais S, Meintjes G, Pepper DJ, Dodd LE, Schutz C, Ismail Z, et al. Frequency, severity, and prediction of tuberculous meningitis immune reconstitution inflammatory syndrome. Clin Infect Dis. 2013;56(3):450–60. https://doi.org/10.1093/cid/cis899.
85. Pepper DJ, Marais S, Maartens G, Rebe K, Morroni C, Rangaka MX, et al. Neurologic manifestations of paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome: a case series. Clin Infect Dis. 2009;48(11):e96–107. https://doi.org/10.1086/598988.
86. Marais S, Wilkinson KA, Lesosky M, Coussens AK, Deffur A, Pepper DJ, et al. Neutrophil-associated central nervous system inflammation in tuberculous meningitis immune reconstitution inflammatory syndrome. Clin Infect Dis. 2014;59(11):1638–47. https://doi.org/10.1093/cid/ciu641.
87. Marais S, Lai RPJ, Wilkinson KA, Meintjes G, O'Garra A, Wilkinson RJ. Inflammasome activation underlying central nervous system deterioration in HIV-associated tuberculosis. J Infect Dis. 2017;215(5):677–86. https://doi.org/10.1093/infdis/jiw561.
88. Meintjes G, Wilkinson RJ, Morroni C, Pepper DJ, Rebe K, Rangaka MX, et al. Randomized placebo-controlled trial of prednisone for paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome. AIDS. 2010;24(15):2381–90. https://doi.org/10.1097/QAD.0b013e32833dfc68.
89. Bell LC, Breen R, Miller RF, Noursadeghi M, Lipman M. Paradoxical reactions and immune reconstitution inflammatory syndrome in tuberculosis. Int J Infect Dis. 2015;32:39–45. https://doi.org/10.1016/j.ijid.2014.12.030.
90. Carvalho AC, De Iaco G, Saleri N, Pini A, Capone S, Manfrin M, et al. Paradoxical reaction during tuberculosis treatment in HIV-seronegative patients. Clin Infect Dis. 2006;42(6):893–5. https://doi.org/10.1086/500459.
91. Garg RK, Malhotra HS, Kumar N. Paradoxical reaction in HIV negative tuberculous meningitis. J Neurol Sci. 2014;340(1–2):26–36. https://doi.org/10.1016/j.jns.2014.03.025.
92. Geri G, Passeron A, Heym B, Arlet JB, Pouchot J, Capron L, et al. Paradoxical reactions during treatment of tuberculosis with extrapulmonary manifestations in HIV-negative patients. Infection. 2013;41(2):537–43. https://doi.org/10.1007/s15010-012-0376-9.
93. • Tai ML, Nor HM, Kadir KA, Viswanathan S, Rahmat K, Zain NR, et al. Paradoxical manifestation is common in HIV-negative tuberculous meningitis. Medicine (Baltimore). 2016;95(1):e1997. https://doi.org/10.1097/md.0000000000001997. This prospective study among HIV-uninfected persons at two centers in Malaysia evaluated the frequency of paradoxical worsening of TB meningitis after treatment initiation. This phenomenon occurred in more than half of the patients, with high rates of recurrence. The frequency was higher than previous estimates. New findings on neuroimaging and clinical deterioration were the most common features of paradoxical worsening.
94. Meintjes G, Lawn SD, Scano F, Maartens G, French MA, Worodria W, et al. Tuberculosis-associated immune reconstitution inflammatory syndrome: case definitions for use in resource-limited settings. Lancet Infect Dis. 2008;8(8):516–23.
95. Abdool Karim SS, Naidoo K, Grobler A, Padayatchi N, Baxter C, Gray A, et al. Timing of initiation of antiretroviral drugs during tuberculosis therapy. N Engl J Med. 2010;362(8):697–706. https://doi.org/10.1056/NEJMoa0905848.
96. Abdool Karim SS, Naidoo K, Grobler A, Padayatchi N, Baxter C, Gray AL, et al. Integration of antiretroviral therapy with tuberculosis treatment. N Engl J Med. 2011;365(16):1492–501. https://doi.org/10.1056/NEJMoa1014181.
97. Havlir DV, Kendall MA, Ive P, Kumwenda J, Swindells S, Qasba SS, et al. Timing of antiretroviral therapy for HIV-1 infection and tuberculosis. N Engl J Med. 2011;365(16):1482–91. https://doi.org/10.1056/NEJMoa1013607.
98. Kendall MA, Nyirenda M, Wu X, Ive P, Benson CA, Andersen JW, et al. Tuberculosis immune reconstitution inflammatory syndrome in A5221 STRIDE: timing, severity and implications for HIV-TB programs. J Acquir Immune Defic Syndr. 2014;65(4):423.
99. Naidoo K, Yende-Zuma N, Padayatchi N, Naidoo K, Jithoo N, Nair G, et al. The immune reconstitution inflammatory syndrome after antiretroviral therapy initiation in patients with tuberculosis: findings from the SAPiT trial. Ann Intern Med. 2012;157(5):313–24. https://doi.org/10.7326/0003-4819-157-5-201209040-00004.
100. •• Torok ME, Yen NT, Chau TT, Mai NT, Phu NH, Mai PP, et al. Timing of initiation of antiretroviral therapy in human immunodeficiency virus (HIV)-associated tuberculous meningitis. Clin Infect Dis. 2011;52(11):1374–83. https://doi.org/10.1093/cid/cir230. After a large study from South Africa of HIV-infected TB patients demonstrated unequivocally that early initiation of antiretroviral therapy (ART) dramatically improved survival, this study evaluated whether a similar strategy could be applied to patients with TB meningitis. In a randomized, double-blind, placebo-controlled trial, patients living with HIV and diagnosed with TB meningitis were randomized to start ART within 7 days of TB treatment or after 2 months of TB treatment. Immediate ART in patients with TB meningitis did not improve survival, and was associated with higher risk of adverese events.
101. Makadzange AT, Ndhlovu CE, Takarinda K, Reid M, Kurangwa M, Gona P, et al. Early versus delayed initiation of antiretroviral therapy for concurrent HIV infection and cryptococcal meningitis in sub-saharan Africa. Clin Infect Dis. 2010;50(11):1532–8. https://doi.org/10.1086/652652.
102. Boulware DR, Meya DB, Muzoora C, Rolfes MA, Huppler Hullsiek K, Musubire A, et al. Timing of antiretroviral therapy after diagnosis of cryptococcal meningitis. N Engl J Med. 2014;370(26):2487–98. https://doi.org/10.1056/NEJMoa1312884.